Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure : The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial

Chronic heart failure remains a major cause of mortality and morbidity. The role of antithrombotic therapy in patients with chronic heart failure has long been debated. The objective of this study was to determine the optimal antithrombotic agent for heart failure patients with reduced ejection frac...

Full description

Saved in:
Bibliographic Details
Published in:Circulation (New York, N.Y.) N.Y.), 2009-03, Vol.119 (12), p.1616-1624
Main Authors: MASSIE, Barry M, COLLINS, Joseph F, TEO, Koon, WARREN, Stuart R, AMMON, Susan E, ARMSTRONG, Paul W, CLELAND, John G. F, EZEKOWITZ, Michael, JAFRI, Syed M, KROL, William F, O'CONNOR, Christopher M, SCHULMAN, Kevin A
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Aspirin - administration & dosage
Biological and medical sciences
Blood and lymphatic vessels
Cardiology. Vascular system
Cardiovascular system
Chronic Disease
Death
Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous
Double-Blind Method
Female
Fibrinolytic Agents - administration & dosage
Heart Failure - complications
Heart Failure - drug therapy
Heart Failure - mortality
Humans
Male
Medical sciences
Middle Aged
Myocardial Infarction
Pharmacology. Drug treatments
Stroke
Stroke Volume
Ticlopidine - administration & dosage
Ticlopidine - analogs & derivatives
Vasodilator agents. Cerebral vasodilators
Warfarin - administration & dosage
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chronic heart failure remains a major cause of mortality and morbidity. The role of antithrombotic therapy in patients with chronic heart failure has long been debated. The objective of this study was to determine the optimal antithrombotic agent for heart failure patients with reduced ejection fractions who are in sinus rhythm. This prospective, randomized clinical trial of open-label warfarin (target international normalized ratio of 2.5 to 3.0) and double-blind treatment with either aspirin (162 mg once daily) or clopidogrel (75 mg once daily) had a 30-month enrollment period and a minimum of 12 months of treatment. We enrolled 1587 men and women >/=18 years of age with symptomatic heart failure for at least 3 months who were in sinus rhythm and had left ventricular ejection fraction of
ISSN:0009-7322
1524-4539
DOI:10.1161/CIRCULATIONAHA.108.801753